Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Epicrispr builds case for FSHD treatment with updated data for EPI-321

Epicrispr Biotechnologies continued to show encouraging findings from testing of its epigenetic editing treatment for the genetic muscle disease facioscapulohumeral muscular dystrophy. Twelve people have been dosed with the therapy, EPI-321, as part of the ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Monday 5 October →